Far-infrared Therapy as a Novel Treatment for Encapsulating Peritoneal Sclerosis

July 1, 2015

Letters to the Editor

......A 45-year-old man with a medical history of end-stage renal disease was admitted owing to abdominal fullness, vomiting, and poor appetite for 1 month. The patient had received 13 years of PD followed by removal of the PD catheter owing to refractory peritonitis, resulting in a shift to hemodialysis 2 months before this admission. A physical examination showed a body temperature of 36.5 °C, a

distended abdomen and hypoactive bowel sounds. Th e dialysate effluent was dark red in appearance. Laboratory examinations

revealed normal blood leukocyte count (WBC: 7,100/mm3 ) but an elevated C-reactive protein level (50.3 mg/l). An abdominal radiograph was obtained to evaluate his symptoms. The intestinal wall was outlined by continuous calcifications (Figure 1 , arrows), and the curvilinear calcification on the right side of the radiograph was peritoneal calcification (Figure 1, white arrows). A contrast enhanced

computed tomography scan demonstrated fluid within the abdomen surrounded by thickened, enhancing peritoneum. The adherent bowel loops were collected centrally by the encapsulating calcified peritoneum, supporting the diagnosis of EPS (Figure 2, white

arrows).


Aft er 3 months of far-infrared therapy, his bowel movement improved. He was able to tolerate a regular oral diet and the color of the dialysate effluent became lightly pink. Because of the improvement in the symptoms aft er far-infrared therapy, our patient decided to follow a conservative treatment plan. Follow-up contrast-enhanced computed tomography scan showed an improvement in dilated loops of small bowel (Figure 3, white arrows). Remarkably, his nutritional status also improved with a significant increase of serum albumin level from 2.7 to 4.2 g/dl, as well as body weight from 59.1 to 62.9 kg aft er far-infrared therapy for 12 months....

-Am J Gastroenterol. 2014 Dec;109(12):1957-9.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
August 19, 2026
A new study published in Cells has provided further insight into the molecular responses of arterial endothelial cells following far-infrared (FIR) irradiation.  The study, conducted by researchers from Gunma Paz University, Japan, investigated the effects of FIR on human femoral artery endothelial cells (HFAECs) using an integrated multi-omics approach combining transcriptomics, proteomics, and phosphoproteomics. FIR irradiation was delivered using the WSTM TY101F far-infrared therapy unit manufactured by WS Far Infrared Medical Technology.
FIRAPY at MEDICA 2026 | Innovative Care for Dialysis Patients
August 19, 2026
Meet FIRAPY at MEDICA 2026 in Düsseldorf, November 16–19. Visit Hall 16, Booth B03-2 to explore innovative far infrared therapy for dialysis patient care.
More Posts